Venatorx Pharmaceuticals Raises $42 Million Series B: Versant, Abingworth, Foresite Back Industry-leading Antibiotics Developer Malvern, PA, July 25, 2017 — Venatorx Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation antibiotics, today announced that it has raised $42 million in a Series B financing led by Versant Ventures and joined by Abingworth and Foresite Capital. Proceeds will...
Category: News
VenatoRx Raises $42 Million Series B: Versant, Abingworth, Foresite Back Industry-leading Antibiotics Developer
VenatoRx Raises $42 Million Series B: Versant, Abingworth, Foresite Back Industry-leading Antibiotics Developer Malvern, PA, July 25, 2017 — VenatoRx Pharmaceuticals, Inc., a biopharmaceutical company developing next-generation antibiotics, today announced that it has raised $42 million in a Series B financing led by Versant Ventures and joined by Abingworth and Foresite Capital. Proceeds will be...
Absorption, Distribution, and Excretion of [14C]-APX001 after Single-Dose Administration to Rats and Monkeys
Absorption, Distribution, and Excretion of [14C]-APX001 after Single-Dose Administration to Rats and Monkeys READ FULL TEXT
First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects READ FULL TEXT
Venatorx Pharmaceuticals Appoints Dr. Michael Diem To The Board Of Directors
Venatorx Pharmaceuticals Appoints Dr. Michael Diem To The Board Of Directors Malvern, PA, September 12, 2016 — Venatorx Pharmaceuticals today announced the appointment of Dr. Michael Diem to its Board of Directors. Dr. Diem is Senior Vice President, Business and Corporate Development at Medgenics, heading all business and corporate development activities for the company. Mike...
VenatoRx Appoints Dr. Michael Diem To The Board Of Directors
VenatoRx Appoints Dr. Michael Diem To The Board Of Directors Malvern, PA, September 12, 2016 — VenatoRx Pharmaceuticals today announced the appointment of Dr. Michael Diem to the VenatoRx Board of Directors. Dr. Diem is Senior Vice President, Business and Corporate Development at Medgenics, heading all business and corporate development activities for the company. Mike...
Bacterioscan Inc. And VenatoRx Pharmaceuticals Collaborate to Improve Antibiotic Drug Development
Bacterioscan Inc. And VenatoRx Pharmaceuticals Collaborate to Improve Antibiotic Drug Development St. Louis, MO, July 14, 2015 — BacterioScan Inc. announced a collaboration with VenatoRx Pharmaceuticals Inc., Malvern, PA, to help reduce the cost and time associated with antimicrobial drug discovery and development. Antibiotics are among the most successful medical breakthroughs in the history of medicine and it is well known...
Dr. Tim Henkel Joins VenatoRx As Chief Medical Officer
Dr. Tim Henkel Joins VenatoRx As Chief Medical Officer Malvern, PA, January 1, 2015 — Dr. Tim Henkel has joined VenatoRx Pharmaceuticals as Chief Medical Officer. Dr. Henkel has spent 20 years in the biopharmaceutical industry developing antibacterial, antifungal, antiviral, immunomodulatory and oncology drugs. He has successfully developed biologics, small molecules and natural products in...
Dr. Tim Henkel Joins Venatorx Pharmaceuticals As Chief Medical Officer
Dr. Tim Henkel Joins Venatorx Pharmaceuticals As Chief Medical Officer Malvern, PA, January 1, 2015 — Dr. Tim Henkel has joined Venatorx Pharmaceuticals as Chief Medical Officer. Dr. Henkel has spent 20 years in the biopharmaceutical industry developing antibacterial, antifungal, antiviral, immunomodulatory and oncology drugs. He has successfully developed biologics, small molecules and natural products...
James G. Murphy Joins VenatoRx As Chief Financial Officer
James G. Murphy Joins VenatoRx As Chief Financial Officer Malvern, PA, November 13, 2014 — Jim Murphy has joined VenatoRx as Chief Financial Officer. Jim has over 25 years’ experience as a senior financial executive in public and privately held companies in the life sciences and the media and technology industries. He has served as...